Randomized phase II trial of single agent erlotinib vs. standard chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) and performance status (PS) of 2

Rogerio Lilenbaum,R. Axerold,S Thomas,Afshin Dowlati,L. Seigel,D. Albert,C. van Duym,D Bodkin

Randomized phase II trial of single agent erlotinib vs. standard chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) and performance status (PS) of 2

2006

Rogerio Lilenbaum
R. Axerold
S Thomas
Afshin Dowlati
L. Seigel
D. Albert
C. van Duym
D Bodkin

7022 Background: A previous CALGB trial suggested a benefit for carboplatin-paclitaxel (CP) over P alone in pts with PS 2. Erlotinib (E) has activity in previously treated pts with low PS but has n...

Keywords:

Performance status
non-small cell lung cancer (NSCLC)
Cancer research
Erlotinib
Oncology
Chemotherapy
Internal medicine
Medicine
previously treated
in patient
single agent

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations